Humira Rivals Set to Try to Drive Down Cost of Blockbuster Drug

An alternative to AbbVie Inc.‘s blockbuster drug Humira officially launched Tuesday, the first in a wave of therapies that will put to the test whether market competition is enough to bring patients lower prices.

The first Humira biosimilar—Amgen Inc.‘s Amjevita—is now available to patients in the US, and the rest of 2023 is poised to bring at least seven additional biosimilars to the high-cost anti-inflammatory drug. Industry members and drug pricing analysts hope the availability of these medicines will drive down costs for patients who rely on the medication for chronic conditions like rheumatoid arthritis.

But policy ...